XDEMVY® (lotilaner ophthalmic solution) 0.25%: Summary

XDEMVY® (lotilaner ophthalmic solution) 0.25%

Biopharmaceutical, healthcare, ophthalmology, therapeutics

Tarsus Pharmaceuticals offers innovative therapies that address significant unmet patient needs, starting with the unique treatment for Demodex blepharitis.

XDEMVY® is the first and only FDA-approved treatment specifically designed for Demodex blepharitis, a prevalent eyelid disease. It aims to provide relief for millions of patients suffering from this condition.

First and only FDA-approved treatment for Demodex blepharitis; Targets diseases with high unmet medical needs; Robust pipeline for future therapies; Commitment to patient-centered care

XDEMVY® is most valuable for patients suffering from Demodex blepharitis, ocular rosacea, and those affected by Lyme disease, providing effective treatment options where none previously existed.

First-mover advantage with XDEMVY® as the only FDA-approved treatment for Demodex blepharitis; Focus on diseases with limited treatment options; Strong leadership and commitment to innovation in biopharmaceuticals

Tarsus Pharmaceuticals is characterized by its innovative pipeline, commitment to addressing high unmet medical needs, and a strong patient-centric approach.

Tarsus positions itself as a leader in developing groundbreaking therapies for diseases with high unmet needs, emphasizing innovation and patient care.

The primary target users include patients suffering from Demodex blepharitis, healthcare providers looking for effective treatment options, and investors interested in innovative biopharmaceutical solutions.

Learn about XDEMVY

• FDA-approved treatment

• Demodex blepharitis

• innovative therapies

• patient care

Revolutionizing treatment for patients in need

Innovative, compassionate, professional

Tarsus stands out in the market due to its scientific approach to creating new treatment categories and its strong commitment to patient care.

Tarsus Pharmaceuticals is identified as a forward-thinking biopharmaceutical company dedicated to revolutionizing treatment for patients through innovative therapies.

2017-01-01

• Bobak Azamian